The applicants, both medical doctors, concluded consultancy agreements with the first respondent, a medical practice. Each agreement contained a clause allowing termination on 30 days' notice and a 'deemed sale' provision forcing the terminating shareholder to sell their 10% shareholding for R1 per share. Disputes arose, and the first respondent gave notice of termination to the second applicant (effective 17 September 2023) and the first applicant (effective 18 November 2023). The applicants launched an urgent application (Part A) to interdict implementation of the termination regarding the first applicant and the forced sale of shares, which was dismissed on 17 November 2023. Part B, seeking relief under s 163 of the Companies Act for the respondents to acquire the applicants' shares at fair market value, was postponed to 24 April 2024. On 14 December 2023, after the first applicant's notice period expired, the respondents sold and transferred both applicants' shares to remaining shareholders, paying each R10. The applicants sought to amend their notice of motion to introduce additional relief, including setting aside the termination and subsequent share sale.